Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond

DOI: 10.21037/cdt.2017.03.02

Keywords: Proprotein convertase subtilisin kexin type 9 (PCSK9), dyslipidemia, LDL-cholesterol, atherosclerosis, cardiovascular disease

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text